Q32 Bio Inc.QTTBEarnings & Financial Report
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
Revenue
$-284.0K
Gross Profit
N/A
Operating Profit
$-9.2M
Net Profit
$-9.5M
Gross Margin
N/A
Operating Margin
3229.2%
Net Margin
3341.2%
YoY Growth
N/A
EPS
$-0.78
Q32 Bio Inc. Q2 FY2025 Financial Summary
Q32 Bio Inc. reported revenue of $-284.0K for Q2 FY2025, with a net profit of $-9.5M (up 44.1% YoY) (3341.2% margin).
Key Financial Metrics
| Total Revenue | $-284.0K |
|---|---|
| Net Profit | $-9.5M |
| Gross Margin | N/A |
| Operating Margin | 3229.2% |
| Report Period | Q2 FY2025 |
Q32 Bio Inc. Annual Revenue by Year
Q32 Bio Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.1M |
| 2024 | $0 |
| 2023 | $1.2M |
| 2022 | $3.2M |
Q32 Bio Inc. Quarterly Revenue & Net Profit History
Q32 Bio Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.9M | — | $57.7M | 2991.2% |
| Q3 FY2025 | $-220.0K | — | $-7.4M | 3358.6% |
| Q2 FY2025 | $-284.0K | — | $-9.5M | 3341.2% |
| Q1 FY2025 | $-371.0K | — | $-11.0M | 2973.3% |
| Q4 FY2024 | $0 | — | $-14.2M | N/A |
| Q3 FY2024 | $0 | — | $-17.6M | N/A |
| Q2 FY2024 | $0 | — | $-17.0M | N/A |
| Q1 FY2024 | $0 | — | $1.0M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $-371000 | $-284000 | $-220000 | $1.9M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $152.3M | $124.2M | $104.5M | $92.3M | $79.1M | $66.1M | $57.8M | $61.8M |
| Liabilities | $103.6M | $90.7M | $86.2M | $86.7M | $83.1M | $78.4M | $76.2M | $19.8M |
| Equity | $48.8M | $33.5M | $18.3M | $5.7M | $-4.0M | $-12.2M | $-18.4M | $42.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.6M | $-22.2M | $-19.5M | $-11.4M | $-12.5M | $-10.7M | $-4.2M | $-6.2M |